CL2008002169A1 - Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios. - Google Patents

Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios.

Info

Publication number
CL2008002169A1
CL2008002169A1 CL2008002169A CL2008002169A CL2008002169A1 CL 2008002169 A1 CL2008002169 A1 CL 2008002169A1 CL 2008002169 A CL2008002169 A CL 2008002169A CL 2008002169 A CL2008002169 A CL 2008002169A CL 2008002169 A1 CL2008002169 A1 CL 2008002169A1
Authority
CL
Chile
Prior art keywords
intermediate compounds
preparing
preparation
triol
pyran
Prior art date
Application number
CL2008002169A
Other languages
English (en)
Inventor
Zhang
Nicole Cathleen Goodwin
Bryce Alden Harrison
Shinya Iimura
Ross Mabon
Qiuling Song
Wenxue Wu
Jie Yan
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CL2008002169A1 publication Critical patent/CL2008002169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Cocristal que comprende un compuesto derivado de tetrahidropirano y un aminoácido aceptable farmacéuticamente; procedimiento de preparación; compuestos intermediarios; procedimiento de preparación, útil para preparar inhibidores del cotransportador de sodio y glucosa 2.
CL2008002169A 2007-07-26 2008-07-24 Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios. CL2008002169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95212207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CL2008002169A1 true CL2008002169A1 (es) 2009-03-20

Family

ID=39877996

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002169A CL2008002169A1 (es) 2007-07-26 2008-07-24 Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios.

Country Status (25)

Country Link
US (2) US8026347B2 (es)
EP (1) EP2183263B1 (es)
JP (2) JP5653213B2 (es)
KR (1) KR101663324B1 (es)
CN (1) CN101801989B (es)
AR (2) AR067701A1 (es)
AT (1) ATE530558T1 (es)
AU (1) AU2008279424B2 (es)
BR (1) BRPI0813840A2 (es)
CA (1) CA2694029C (es)
CL (1) CL2008002169A1 (es)
CO (1) CO6260141A2 (es)
DK (1) DK2183263T3 (es)
EA (1) EA017411B1 (es)
EC (1) ECSP109987A (es)
ES (1) ES2375800T3 (es)
HK (1) HK1143982A1 (es)
IL (1) IL203209A (es)
NZ (1) NZ582536A (es)
PL (1) PL2183263T3 (es)
PT (1) PT2183263E (es)
TW (2) TWI419886B (es)
UA (1) UA107175C2 (es)
WO (1) WO2009014970A1 (es)
ZA (1) ZA201000219B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
HUE040486T2 (hu) 2009-11-13 2019-03-28 Astrazeneca Ab Kétrétegû tabletta készítmények
EP2498757A1 (en) 2009-11-13 2012-09-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
EP2670397B1 (en) 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
TR201903445T4 (tr) 2011-06-01 2019-03-21 Green Cross Corp Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇
BR112013031032A2 (pt) 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
NZ707859A (en) * 2012-11-20 2019-03-29 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose cotransporter 1
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
EP2895490B1 (en) 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN105828815B (zh) 2013-12-17 2020-03-27 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
PL3485890T3 (pl) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
DK3125882T3 (da) 2014-04-01 2020-06-29 Boehringer Ingelheim Vetmedica Gmbh Behandling af metabolske lidelser i hestedyr
JP6727419B2 (ja) * 2016-05-25 2020-07-22 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
KR102226465B1 (ko) * 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
EP3473621B1 (en) 2016-06-17 2021-08-04 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CN107540685B (zh) * 2017-09-04 2020-05-05 杭州科巢生物科技有限公司 一种Sotagliflozin的制备方法及其中间体
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
CN108675976B (zh) * 2018-05-14 2020-07-14 浙江宏元药业股份有限公司 一种6-卤代葡萄糖碳苷及其制备方法和应用
CN112585124B (zh) 2018-08-13 2024-04-19 株式会社大熊制药 用于合成sglt抑制剂的中间体的制备方法
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
WO2021105152A1 (en) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors in the drying-off of non-human mammals
JP7423800B2 (ja) 2020-02-17 2024-01-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用
AU2022318037A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
NZ521369A (en) * 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
CA2429833A1 (en) * 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
KR20050005442A (ko) * 2002-04-12 2005-01-13 아칠리온 파르마세우티칼스 인코포레이티드 β-Ｌ-플루오로-2',3'-디데히드로사이티딘(β-Ｌ-ＦＤ4Ｃ)의합성 방법
AU2003254904A1 (en) * 2002-08-09 2004-02-25 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-beta-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
CN101260130A (zh) * 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
US7368475B2 (en) * 2003-03-12 2008-05-06 Kemin Pharma Bvba Furanose-type bicyclic carbohydrates with biological activity
MXPA05009356A (es) * 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602006009772D1 (de) * 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008044268A1 (fr) * 2006-10-05 2008-04-17 Panasonic Corporation Appareil et procédé de transmission
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
JP5653213B2 (ja) 2015-01-14
US20090030198A1 (en) 2009-01-29
TWI506024B (zh) 2015-11-01
KR20100040869A (ko) 2010-04-21
EA201070186A1 (ru) 2010-08-30
AU2008279424A1 (en) 2009-01-29
US8293878B2 (en) 2012-10-23
BRPI0813840A2 (pt) 2017-06-06
PL2183263T3 (pl) 2012-03-30
CN101801989B (zh) 2015-11-25
DK2183263T3 (da) 2012-01-30
JP2010534661A (ja) 2010-11-11
AR112669A2 (es) 2019-11-27
CA2694029C (en) 2016-10-04
KR101663324B1 (ko) 2016-10-06
US8026347B2 (en) 2011-09-27
CA2694029A1 (en) 2009-01-29
AR067701A1 (es) 2009-10-21
TW201350473A (zh) 2013-12-16
EP2183263B1 (en) 2011-10-26
TW200914434A (en) 2009-04-01
IL203209A (en) 2014-02-27
CN101801989A (zh) 2010-08-11
AU2008279424B2 (en) 2013-06-13
EA017411B1 (ru) 2012-12-28
US20120095197A1 (en) 2012-04-19
NZ582536A (en) 2012-01-12
JP2014001230A (ja) 2014-01-09
TWI419886B (zh) 2013-12-21
ES2375800T3 (es) 2012-03-06
UA107175C2 (uk) 2014-12-10
JP5764174B2 (ja) 2015-08-12
ZA201000219B (en) 2011-03-30
EP2183263A1 (en) 2010-05-12
CO6260141A2 (es) 2011-03-22
PT2183263E (pt) 2012-01-11
WO2009014970A1 (en) 2009-01-29
ECSP109987A (es) 2010-03-31
HK1143982A1 (zh) 2011-01-21
ATE530558T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
CL2008002169A1 (es) Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios.
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
UY32490A (es) Inhibidores de beta-secretasa
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
UY32062A (es) Inhibidores de beta-secretasa
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
CR20120626A (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta- D-glucopiranosil)-2-tienilmetil]benceno como inhibidores de los transportadores de glucosa dependientes de sodio (SGLT)
NO20065719L (no) I det vesentlige rene 2-{[2-(2-metylamino-pyrimidin-4-yl)-1H-indol-5-karbonyl]-amlno}-3-(fenylpyridin-2-yl-amino)-propionsyre som en IkB kinaseinhibitor.
BR112013028877A2 (pt) derivados de piperidina e composições para a inibição de nicotinamida fosforibosiltransferase (nampt)
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
BR112019004449A2 (pt) heparina biossintética
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
WO2008001391A3 (en) Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
DK1931636T3 (da) Isoquinoliner som IGF-1R-inhibitorer
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.